We are currently experiencing issues with the translation of certain words in languages other than English.

The facts on Acrylonitrile

Table of contents

The facts on Acrylonitrile

Last update March 18, 2025

Approximatively 10,000 to 33,000 workers in the EU are exposed to acrylonitrile at their workplaces. Inhalation is considered as the primary route of exposure although workers can be exposed through dermal contact as well as acrylonitrile can readily penetrate the skin.

Acrylonitrile is classified as Carcinogenic Category 1B (according to CLP regulation), which means it is presumed to have carcinogenic potential for humans, based on animal evidence. The exposure to acrylonitrile can cause lung cancer and there is evidence that acrylonitrile can cause bladder cancer.

Where risks occur

The primary use of acrylonitrile is as the raw material for the manufacture of acrylic and modacrylic textile fibres. Other major uses include the manufacture of chemicals, rubber products and plastic products; acrylonitrile and styrene are also used together in the production of styrene–acrylonitrile (SAN) and acrylonitrile–butadiene–styrene (ABS) resins.

More about the substance

At normal temperature and pressure, acrylonitrile is a clear, colorless liquid that has a pungent odor. Small amounts of acrylonitrile are released during the combustion of plant matter such as biomass, timber and tobacco. Acrylonitrile is widely used in the aircraft, defense, aerospace and automotive sectors.

Hazards that may occur

When breathed in or absorbed via skin contact, the primary target for toxicity is the central nervous system.

Acrylonitrile can also locally irritate skin, eyes and respiratory tract, and skin sensitisation. Part of this toxicity is due to the metabolism of acrylonitrile to cyanide.

At higher exposure levels, acrylonitrile is also associated with other effects such as limb weakness, laboured breathing, dizziness, impaired judgement, cyanosis and nausea, through to collapse, irregular breathing and convulsions, depending on dose and duration of exposure.

Acute inhalation exposure to liquid or vapour forms of acrylonitrile (often occurring as a result of accidental release) has been associated with a range of effects including irritation of the mucous membranes of the nose, eyes and upper respiratory tract.

With regard to the latency period between exposure and acrylonitrile related brain cancer, a 30 years latency period.

What you can do

At the workplace, the most effective way to prevent exposure is by substitution of acrylonitrile, for example in the manufacture of ABS it can be replaced by methacrylonitrile (2-methyl-2-propene-nitrile). Where substitution of acrylonitrile is not possible and use of acrylonitrile cannot be avoided, measures to reduce exposure must be taken.

The most effective way to avoid exposure to acrylonitrile is to develop and use closed systems. Where this is not possible, technical measures such as effective local exhaust ventilation, supplemented by good ventilation of the workplace as well as checking their effectiveness should be implemented to ensure that exposure is minimised as much as technically possible.

Implement regular exposure assessments to check if your protective measures in place are effective or whether further actions need to be taken. Workers need to be aware of the effects of exposure and should be trained regularly on the control measures necessary for working safely with acrylonitrile to prevent exposure. Involving an occupational physician is recommended.

Ensure that workers have adequate personal protective equipment, such as protective clothing and gloves, if necessary. Personal protective equipment should not be used as the only preventive measure. As many of the above technical and organisational measures as possible must have been implemented beforehand. Make sure the right personal protective equipment is used, like eyes and face protection, gloves, protective clothing and breathing protection. In addition, when selecting equipment, the anatomy of the workers who will be using it must be taken into account and, in the case of respiratory protective equipment based on facial adjustment, it is highly recommended that a fit test be carried out on each person. Additionally, all workers should be instructed to wash their hands properly before taking a break or entering another area, and to wash themselves and change their clothes at the end of each shift.

Personal protective equipment should only be used as a last resort and only considered temporarily, after the possible technical solutions have been exhausted. Workers should receive the necessary training and information for the correct use and maintenance of PPE.

References:, CLP, IARC, Impact Assessment, RAC

Limit values

EU
1 mg/m³

 Austria

4,5 mg/m³ (TWA)
18 mg/m³ Short term
 Belgium
4,4 mg/m³
Bulgaria
EU directive
Croatia
EU directive
Czech Republic
EU directive
Cyprus
EU directive
Denmark
EU directive
Estonia
4 mg/m³ (TWA)
8 mg/m³ Short term
Finland
4,4 mg/m³ (TWA)
8,8 mg/m³ short term
France
4,5 mg/m³ (TWA)
32,5 mg/m³ short term
Germany
2,6 mg/m³ (tolerance)
0,26 mg/m³ (acceptance)
Greece
EU directive
Hungary
4,3 mg/m³ (TWA)
Iceland
EU directive
Ireland
4,5 mg/m³ (TWA)
Italy
EU directive
Latvia
EU directive
Lithuania
EU directive
Luxembourg
EU directive
Malta
EU directive
Netherlands
EU directive
North Macedonia
7 mg/m³ (TWA)
28 mg/m³ short term
Norway
4 mg/m³ (TWA)
Poland
2 mg/m³ (TWA)
10 mg/m³
Portugal
EU directive
Romania
5 mg/m³ (TWA)
10 mg/m³
Serbia
EU directive
Slovakia
EU directive
 Slovenia
EU directive
Spain
4,4 mg/m³ (TWA)
Sweden
4,5 mg/m³ (TWA)
13mg/m³
Turkey
EU directive

References: cancer.gov, EFSA, IARC, EC, NIOSH, OSHA, CAREX

Please be aware that for this carcinogen you need to be more cautious when determining potential skin contact and how to regard dermal exposure in your risk reduction strategy.
ECHA registration
CAS number 107-13-1
EC number 203-466-5
Annex VI of CLP 1B
Number of registrations (2023) 134
Tonnage band registred (2023) ≥ 1.000.000 to < 10.000.000

The European Chemicals Agency (ECHA) works for the safe use of chemicals. It implements the EU’s groundbreaking chemicals legislation, benefiting human health, the environment and innovation and competitiveness in Europe.

GESTIS Database

The data pool may be used for the purpose of occupational health and safety or to obtain information on the hazards posed by chemical substances.

General facts

Facts about cancer-causing agents:

  • The direct costs of carcinogen exposure at work across Europe are estimated at 2.4 billion Euros per year.
  • Every year, about 120.000 persons get cancer from exposure to carcinogens at work
  • Annually more than 100.000 people die because of work-related cancer.
Table of contents

Sign up for our newsletter to become part of our community. Or follow us on LinkedIn and join the conversation!